This article is for premium subscribers!
To read further, please sign up for a premium subscription. You can also read more about standard and premium subscriptions here. Your subscription dollars are tax deductible and support the in-depth stories you appreciate from The Lund Report. If you believe you already are a premium subscriber, you are already logged in, and you are getting this message, please contact [email protected] Thanks!
If you are a premium subscriber that is not logged in, please login now.
SALEM – For six years, Oregon pharmacies have been lobbying the state Legislature to rein in fees imposed on them by pharmacy benefit managers, the third-party intermediaries that negotiate prices with drug manufacturers and prescription drug claims with insurers.
Medicare enrollees, who have watched their out-of-pocket spending on prescription drugs climb in recent years, might be in for a break.
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found.
Who contributes to what you pay at the pharmacy? Why are prescription drugs so expensive in the United States?
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong. Khot is a cardiologist at the Cleveland Clinic, which prides itself on outstanding heart care. The health system’s pharmacists had alerted doctors about the skyrocketing cost of the drugs, nitroprusside and isoproterenol. But these two older drugs, frequently used in emergency and intensive care situations, have no direct alternatives.
The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.
With prescription drug prices soaring and President Donald Trump vowing to take action, an old idea is gaining fresh traction: allowing Americans to buy medicines from foreign pharmacies at far lower prices.
Before Luke Whitbeck began taking a $300,000-a-year drug, the 2-year-old’s health was inexplicably failing.
A pale boy with enormous eyes, Luke frequently ran high fevers, tired easily and was skinny all over, except his belly stuck out like a bowling ball.
High cost specialty drugs have begun outpacing hospital expenditures, and public officials, lawmakers and consumer advocates are hard at work trying to figure out how to get a handle on this growing problem.